Metagenomi Therapeutics MGX
NASDAQ MGX
$1.11 +0.05 (+4.23%)
As of: Oct 1, 2026 · 3:38 PM EDT

Metagenomi Therapeutics (MGX) Preferred Stock Liabilities (2023)

Updated

Metagenomi Therapeutics' Preferred Stock Liabilities came in at $350.76 million for Q4 2023, unchanged from the prior quarter.

Analysis

Metagenomi Therapeutics (MGX) Preferred Stock Liabilities (2023) Analysis & Trends

Going back to Q1 2023, Metagenomi Therapeutics' Preferred Stock Liabilities data covers 4 quarters.

  • Business Quant data shows MGX's Preferred Stock Liabilities at $350.76 million (Q3 2023), $350.76 million (Q2 2023) and $350.76 million (Q1 2023) in the three quarters before Q4 2023.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Preferred Stock Liabilities (Qtr)
1 Johnson & Johnson 638.12 Bn 556.64 Bn 17.26 Bn -
2 AbbVie 462.60 Bn 435.75 Bn 12.70 Bn -
3 Merck 358.70 Bn 313.13 Bn 12.21 Bn -
4 Novartis Ag 272.16 Bn 228.03 Bn 11.24 Bn -
5 Astrazeneca 250.36 Bn 223.92 Bn 12.86 Bn -
6 Amgen 227.87 Bn 183.27 Bn 7.24 Bn -
7 Gilead Sciences 184.97 Bn 159.08 Bn 6.22 Bn -
8 Pfizer 162.61 Bn 109.56 Bn 10.94 Bn -
9 Vertex Pharmaceuticals 132.45 Bn 104.46 Bn 2.84 Bn -
10 Metagenomi Therapeutics 40.04 Mn 40.04 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2023 350.76 Mn
Sep 30, 2023 350.76 Mn
Jun 30, 2023 350.76 Mn
Mar 31, 2023 350.76 Mn
API Access

Metagenomi Therapeutics Preferred Stock Liabilities API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=preferred-stock-liabilities&ticker=MGX&period=max&api_key=YOUR_API_KEY